<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-26655" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Parasympathomimetic Medications</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Neesirg M.</given-names>
          </name>
          <aff>Oakland University William Beaumont SOM</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dewaswala</surname>
            <given-names>Nakeya</given-names>
          </name>
          <aff>University of Miami / JFK Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Neesirg Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nakeya Dewaswala declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-26655.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Parasympathomimetics are a class of medications that activate the parasympathetic nervous system by mimicking or modifying the effects of acetylcholine. These drugs include muscarinic receptor agonists (direct-acting parasympathomimetics) and acetylcholinesterase inhibitors (indirect-acting parasympathomimetics). This activity reviews the indications, contraindications, activity, adverse events, and other key elements of parasympathomimetic therapy in the clinical setting pertinent to interprofessional team members managing the care of patients receiving these medications.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of parasympathomimetic medications.</p></list-item><list-item><p>Describe the potential adverse effects of parasympathomimetic medications.</p></list-item><list-item><p>Review the appropriate monitoring of parasympathomimetic medications.</p></list-item><list-item><p>Discuss interprofessional team strategies for improving care coordination and communication to advance parasympathomimetic therapy and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26655&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26655">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-26655.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Parasympathomimetics are a class of pharmacological agents that activate the parasympathetic division of the autonomic nervous system. These drugs work by mimicking or modifying the effects of acetylcholine (ACh), the primary neurotransmitter of the parasympathetic nervous system. Parasympathomimetic medications are classified&#x000a0;into two main categories based on whether they are direct agonists or indirect agonists of ACh. Direct agonists directly bind and activate muscarinic ACh receptors, while indirect agonists increase synaptic levels of ACh by inhibiting the enzyme acetylcholinesterase. Listed below are the major indications for various parasympathomimetic drugs:</p>
        <p>
<bold>Direct-Acting Parasympathomimetics</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Bethanechol: Urinary retention, postoperative and neurogenic ileus</p>
          </list-item>
          <list-item>
            <p>Carbachol: Induction of miosis, open-angle glaucoma</p>
          </list-item>
          <list-item>
            <p>Cevimeline: Xerostomia (especially in Sj&#x000f6;gren syndrome)<xref ref-type="bibr" rid="article-26655.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>Methacholine: Challenge test to assess airway hyperresponsiveness in the clinical diagnosis of asthma<xref ref-type="bibr" rid="article-26655.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Pilocarpine: Induction of sweating, lacrimation, and salivation, open-angle, and closed-angle glaucoma</p>
          </list-item>
        </list>
        <p>
<bold>Indirect-Acting Parasympathomimetics</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Donepezil, Rivastigmine, and Galantamine: Alzheimer disease<xref ref-type="bibr" rid="article-26655.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Edrophonium: Historically used in the diagnosis of myasthenia gravis<xref ref-type="bibr" rid="article-26655.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Neostigmine: Postoperative and neurogenic ileus and urinary retention, myasthenia gravis, postoperative reversal of neuromuscular blockade</p>
          </list-item>
          <list-item>
            <p>Physostigmine: Antidote for anticholinergic toxicity<xref ref-type="bibr" rid="article-26655.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Pyridostigmine: Myasthenia gravis<xref ref-type="bibr" rid="article-26655.r6">[6]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26655.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Direct-acting parasympathomimetic agents act at muscarinic ACh receptors to mimic the physiologic effects resulting from activation of the parasympathetic nervous system. All muscarinic receptor subtypes (M1-M5) are G protein-coupled receptors linked to intracellular signal transduction pathways. Binding of direct agonists to Gq-coupled M1, M3, and M5 receptor subtypes stimulates phospholipase C, which initiates the phosphatidylinositol signaling cascade, ultimately leading to the mobilization of intracellular calcium and activation of protein kinase C. Binding of direct agonists to Gi/o-coupled M2 and M4 receptor subtypes leads to inhibition of adenylyl cyclase activity, resulting in decreased levels of cyclic AMP, and to increased potassium conductance, resulting in hyperpolarization of the membrane potential.<xref ref-type="bibr" rid="article-26655.r7">[7]</xref><xref ref-type="bibr" rid="article-26655.r8">[8]</xref></p>
        <p>The five subtypes of muscarinic ACh receptors have varying distributions throughout the central nervous system and periphery. For example, M1 receptors are mainly&#x000a0;found in cortical regions of the brain, autonomic ganglia, glands (gastric and salivary), and enteric nerves. M2 receptors are predominantly expressed in cardiac and smooth muscle. M3 receptors are abundant in exocrine glands, smooth muscle, and vascular endothelium.<xref ref-type="bibr" rid="article-26655.r9">[9]</xref></p>
        <p>The parasympathomimetic effects of indirect-acting agents are mediated by their inhibitory effect on the hydrolysis of endogenous ACh at cholinergic synapses by acetylcholinesterase. Increased synaptic concentrations of ACh result in prolonged stimulation of cholinergic receptors throughout the central and peripheral nervous systems.<xref ref-type="bibr" rid="article-26655.r10">[10]</xref></p>
        <p>The significant effects of parasympathomimetic medications are summarized below by organ system:</p>
        <list list-type="bullet">
          <list-item>
            <p>Eye
<list list-type="bullet"><list-item><p>Contraction of the sphincter pupillae muscle (miosis)</p></list-item><list-item><p>Contraction of the ciliary muscle (accommodation for near vision)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Cardiovascular
<list list-type="bullet"><list-item><p>Vasodilation (via endothelium-derived relaxing factor)</p></list-item><list-item><p>Decrease in firing rate of the sinoatrial node (negative chronotropy)</p></list-item><list-item><p>Decrease in conduction velocity through the atrioventricular node (negative dromotropy)</p></list-item><list-item><p>Decrease in contractile strength of the atria (negative inotropy)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal
<list list-type="bullet"><list-item><p>Stimulation of salivary and gastric glands</p></list-item><list-item><p>Increase in gut motility</p></list-item><list-item><p>Relaxation of sphincters</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Urinary
<list list-type="bullet"><list-item><p>Contraction of the detrusor muscle</p></list-item><list-item><p>Relaxation of the trigone and sphincter muscles</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Respiratory
<list list-type="bullet"><list-item><p>Contraction of bronchial smooth muscle</p></list-item><list-item><p>Stimulation of tracheobronchial secretions</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Other Effects
<list list-type="bullet"><list-item><p>Stimulation of secretion from lacrimal, sweat, and nasopharyngeal glands</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26655.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Parasympathomimetic medications are available in a variety of different formulations. For example, topical preparations of carbachol and pilocarpine are available for ophthalmic use in the treatment of glaucoma and the induction of miosis during surgical procedures. Methacholine is administered by oral inhalation for methacholine challenge testing. Pyridostigmine is given orally for the treatment of myasthenia gravis. Neostigmine administration is parenteral for the treatment of paralytic ileus and atony of the urinary bladder.</p>
      </sec>
      <sec id="article-26655.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Most adverse effects of parasympathomimetics are predictable consequences of muscarinic ACh receptor stimulation. Common adverse effects include nausea, vomiting, diarrhea, abdominal cramps, urinary urgency, diaphoresis, salivation, bronchoconstriction, and hypotension. Topical parasympathomimetic medications, such as those used for ophthalmic conditions have a limited adverse event profile.</p>
      </sec>
      <sec id="article-26655.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Parasympathomimetic agents can exacerbate symptoms of COPD, asthma, and peptic ulcer disease in susceptible individuals. Caution is necessary when prescribing these drugs to patients with cardiovascular disease, as they can cause bradycardia and hypotension, which may compromise coronary blood flow.&#x000a0;Parasympathomimetics are contraindicated in patients with hyperthyroidism, as they can precipitate atrial fibrillation in these individuals.<xref ref-type="bibr" rid="article-26655.r11">[11]</xref>&#x000a0;Additionally, these medications are not recommended for use in those with mechanical obstruction of the gastrointestinal or urinary tract.</p>
      </sec>
      <sec id="article-26655.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Health care providers should monitor patients taking parasympathomimetic medications to ensure that treatment achieves the&#x000a0;intended therapeutic effect. Providers must also observe patients closely for possible adverse effects. Overdosage may result in a cholinergic crisis due to the overstimulation of ACh receptors, which can potentially be life-threatening.</p>
      </sec>
      <sec id="article-26655.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Toxicity associated with parasympathomimetic agents is the result of cholinergic excess. Muscarinic effects of cholinergic toxidrome include diarrhea, urination, miosis, bronchospasm, bradycardia, emesis, lacrimation, sweating, and salivation (commonly remembered using the mnemonic &#x0201c;DUMBBELSS&#x0201d;). In the case of overdosage of direct-acting agents, parenteral administration of atropine, a muscarinic antagonist, is used to reverse symptoms via competitive inhibition. Cholinergic toxicity can result from the ingestion of some varieties of mushrooms containing muscarine, particularly those in the genera <italic toggle="yes">Inocybe</italic> and <italic toggle="yes">Clitocybe</italic>.<xref ref-type="bibr" rid="article-26655.r12">[12]</xref></p>
        <p>Acute intoxication by indirect-acting agents initially presents with the aforementioned signs of muscarinic excess. The effects of central nervous system involvement may include altered mental status, convulsions, and coma. Additionally, overstimulation of nicotinic receptors at neuromuscular junctions results in muscle weakness and fasciculations.<xref ref-type="bibr" rid="article-26655.r13">[13]</xref>&#x000a0;Notably, paralysis of the respiratory muscles may occur, a common cause of mortality in these patients.</p>
        <p>Initial management involves the stabilization of the patient. If rapid sequence intubation is required, clinicians should avoid using succinylcholine, which can cause prolonged neuromuscular blockade due to inactivation by acetylcholinesterase. Patients may need to be decontaminated to reduce residual exposure. Rapid administration of atropine in progressively increasing doses is necessary to reverse the effects of muscarinic toxicity. Pralidoxime may work to reactivate the inhibited acetylcholinesterase enzyme and reverse nicotinic effects. Benzodiazepines help to control seizure activity in patients.<xref ref-type="bibr" rid="article-26655.r14">[14]</xref><xref ref-type="bibr" rid="article-26655.r15">[15]</xref></p>
        <p>Acute anticholinesterase toxicity often occurs in the context of accidental exposure to organophosphate compounds used in agricultural pesticides.<xref ref-type="bibr" rid="article-26655.r16">[16]</xref>&#x000a0;Intoxication may also occur from exposure to nerve agents used in chemical warfare, such as sarin and VX.<xref ref-type="bibr" rid="article-26655.r17">[17]</xref></p>
      </sec>
      <sec id="article-26655.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>While parasympathomimetic medications are highly effective in treating several neurological, ophthalmic, gastrointestinal, and urinary disorders, they also carry the potential for adverse effects. All members of the interprofessional health care team, including clinicians, nurses, pharmacists, and other health professionals, should be aware of the side effects and contraindications of parasympathomimetics. Prescribers should consult with the pharmacy team regarding appropriate dosing and potential drug-drug interactions. Furthermore, it is important that health care providers counsel patients on how to take prescribed medications and educate them on potential side effects associated with treatment. Nurses and other clinical staff should be able to recognize the signs of cholinergic toxicity and promptly communicate these findings with other team members in cases of overdosage. Interprofessional collaboration is critical to the effective use of parasympathomimetic medications. By implementing an interprofessional team-based approach to care, providers can achieve optimal patient outcomes while minimizing the risk of adverse events. [Level 5]</p>
      </sec>
      <sec id="article-26655.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26655&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26655">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/26655/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=26655">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-26655.s11">
        <title>References</title>
        <ref id="article-26655.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramos-Casals</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tzioufas</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Sis&#x000f3;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bosch</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Treatment of primary Sj&#x000f6;gren syndrome: a systematic review.</article-title>
            <source>JAMA</source>
            <year>2010</year>
            <month>Jul</month>
            <day>28</day>
            <volume>304</volume>
            <issue>4</issue>
            <fpage>452</fpage>
            <page-range>452-60</page-range>
            <pub-id pub-id-type="pmid">20664046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26655.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crapo</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Casaburi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Coates</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Enright</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Hankinson</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Irvin</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>MacIntyre</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>McKay</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Wanger</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Cockcroft</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Fish</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Sterk</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>161</volume>
            <issue>1</issue>
            <fpage>309</fpage>
            <page-range>309-29</page-range>
            <pub-id pub-id-type="pmid">10619836</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26655.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bonner</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Peskind</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>Pharmacologic treatments of dementia.</article-title>
            <source>Med Clin North Am</source>
            <year>2002</year>
            <month>May</month>
            <volume>86</volume>
            <issue>3</issue>
            <fpage>657</fpage>
            <page-range>657-74</page-range>
            <pub-id pub-id-type="pmid">12171061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26655.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pascuzzi</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>The edrophonium test.</article-title>
            <source>Semin Neurol</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>83</fpage>
            <page-range>83-8</page-range>
            <pub-id pub-id-type="pmid">12870109</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26655.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nilsson</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Physostigmine treatment in various drug-induced intoxications.</article-title>
            <source>Ann Clin Res</source>
            <year>1982</year>
            <month>Aug</month>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>165</fpage>
            <page-range>165-72</page-range>
            <pub-id pub-id-type="pmid">7168546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26655.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanders</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Wolfe</surname>
                <given-names>GI</given-names>
              </name>
              <name>
                <surname>Benatar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Evoli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gilhus</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Illa</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kuntz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Massey</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Melms</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Murai</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nicolle</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Palace</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Richman</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Verschuuren</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Narayanaswami</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>International consensus guidance for management of myasthenia gravis: Executive summary.</article-title>
            <source>Neurology</source>
            <year>2016</year>
            <month>Jul</month>
            <day>26</day>
            <volume>87</volume>
            <issue>4</issue>
            <fpage>419</fpage>
            <page-range>419-25</page-range>
            <pub-id pub-id-type="pmid">27358333</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26655.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wess</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Molecular biology of muscarinic acetylcholine receptors.</article-title>
            <source>Crit Rev Neurobiol</source>
            <year>1996</year>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>69</fpage>
            <page-range>69-99</page-range>
            <pub-id pub-id-type="pmid">8853955</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26655.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nathanson</surname>
                <given-names>NM</given-names>
              </name>
            </person-group>
            <article-title>Molecular properties of the muscarinic acetylcholine receptor.</article-title>
            <source>Annu Rev Neurosci</source>
            <year>1987</year>
            <volume>10</volume>
            <fpage>195</fpage>
            <page-range>195-236</page-range>
            <pub-id pub-id-type="pmid">2436543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26655.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wess</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eglen</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Gautam</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development.</article-title>
            <source>Nat Rev Drug Discov</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>6</volume>
            <issue>9</issue>
            <fpage>721</fpage>
            <page-range>721-33</page-range>
            <pub-id pub-id-type="pmid">17762886</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26655.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Colovi&#x00107;</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Krsti&#x00107;</surname>
                <given-names>DZ</given-names>
              </name>
              <name>
                <surname>Lazarevi&#x00107;-Pa&#x00161;ti</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Bond&#x0017e;i&#x00107;</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Vasi&#x00107;</surname>
                <given-names>VM</given-names>
              </name>
            </person-group>
            <article-title>Acetylcholinesterase inhibitors: pharmacology and toxicology.</article-title>
            <source>Curr Neuropharmacol</source>
            <year>2013</year>
            <month>May</month>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>315</fpage>
            <page-range>315-35</page-range>
            <pub-id pub-id-type="pmid">24179466</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26655.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stavrakis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Patterson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hamlett</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Chalmers</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pappy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Morshed</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Lazzara</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kem</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Activating autoantibodies to the beta-1 adrenergic and m2 muscarinic receptors facilitate atrial fibrillation in patients with Graves' hyperthyroidism.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2009</year>
            <month>Sep</month>
            <day>29</day>
            <volume>54</volume>
            <issue>14</issue>
            <fpage>1309</fpage>
            <page-range>1309-16</page-range>
            <pub-id pub-id-type="pmid">19778674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26655.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berger</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Guss</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Mycotoxins revisited: Part I.</article-title>
            <source>J Emerg Med</source>
            <year>2005</year>
            <month>Jan</month>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>53</fpage>
            <page-range>53-62</page-range>
            <pub-id pub-id-type="pmid">15657006</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26655.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>King</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Aaron</surname>
                <given-names>CK</given-names>
              </name>
            </person-group>
            <article-title>Organophosphate and carbamate poisoning.</article-title>
            <source>Emerg Med Clin North Am</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>133</fpage>
            <page-range>133-51</page-range>
            <pub-id pub-id-type="pmid">25455666</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26655.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eddleston</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Eyer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dawson</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>Management of acute organophosphorus pesticide poisoning.</article-title>
            <source>Lancet</source>
            <year>2008</year>
            <month>Feb</month>
            <day>16</day>
            <volume>371</volume>
            <issue>9612</issue>
            <fpage>597</fpage>
            <page-range>597-607</page-range>
            <pub-id pub-id-type="pmid">17706760</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26655.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Newmark</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Therapy for acute nerve agent poisoning: An update.</article-title>
            <source>Neurol Clin Pract</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>337</fpage>
            <page-range>337-342</page-range>
            <pub-id pub-id-type="pmid">31583189</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26655.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <article-title>Organophosphorus Insecticide Poisoning.</article-title>
            <source>EJIFCC</source>
            <year>1999</year>
            <month>Jul</month>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>30</fpage>
            <page-range>30-35</page-range>
            <pub-id pub-id-type="pmid">30720257</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26655.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holstege</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Kirk</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sidell</surname>
                <given-names>FR</given-names>
              </name>
            </person-group>
            <article-title>Chemical warfare. Nerve agent poisoning.</article-title>
            <source>Crit Care Clin</source>
            <year>1997</year>
            <month>Oct</month>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>923</fpage>
            <page-range>923-42</page-range>
            <pub-id pub-id-type="pmid">9330846</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
